This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baishanbo, A.
Right arrow Articles by Favennec, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baishanbo, A.
Right arrow Articles by Favennec, L.

 Previous Article  |  Next Article 

Infection and Immunity, August 2005, p. 5252-5255, Vol. 73, No. 8
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.8.5252-5255.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Infectivity of Cryptosporidium hominis and Cryptosporidium parvum Genotype 2 Isolates in Immunosuppressed Mongolian Gerbils

Asiya Baishanbo,1 Gilles Gargala,1 Agnès Delaunay,2 Arnaud François,3 Jean-Jacques Ballet,2* and Loïc Favennec1

Laboratoire de Parasitologie, and ADEN EA-3234, CHU Charles Nicolle, Rouen, France,1 Laboratoire d'Immunologie et d'Immunopathologie, UPRES EA-2128, CHU Clemenceau, Caen, France,2 Laboratoire d'Histopathologie, CHU Charles Nicolle, Rouen, France3

Received 29 November 2004/ Returned for modification 4 January 2005/ Accepted 10 March 2005

One-month-old dexamethasone-immunosuppressed Mongolian gerbils were challenged with 1 oocyst to 2 x 105 oocysts from two isolates genotyped as Cryptosporidium hominis and C. parvum (genotype 2), respectively. A similar dose-dependent gut infection was obtained, and the initial genotype maintained for 21 to 22 days. The data suggest that immunosuppressed gerbils provide a reliable rodent model of persistent C. hominis infection.

* Corresponding author. Mailing address: Laboratoire d'Immunologie et d'Immunopathologie, CHU Clemenceau, 14033 Caen Cedex, France. Phone: 33(0)2-31-27-25-51. Fax: 33(0)2-31-27-25-50. E-mail: ballet-jj{at}chu-caen.fr.

Editor: W. A. Petri, Jr.

Infection and Immunity, August 2005, p. 5252-5255, Vol. 73, No. 8
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.8.5252-5255.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Giles, M., Chalmers, R., Pritchard, G., Elwin, K., Mueller-Doblies, D., Clifton-Hadley, F. (2009). Cryptosporidium hominis in a goat and a sheep in the UK. Vet Rec. 164: 24-25 [Full Text]  
  • CHAPPELL, C. L., OKHUYSEN, P. C., LANGER-CURRY, R., WIDMER, G., AKIYOSHI, D. E., TANRIVERDI, S., TZIPORI, S. (2006). CRYPTOSPORIDIUM HOMINIS: EXPERIMENTAL CHALLENGE OF HEALTHY ADULTS. Am J Trop Med Hyg 75: 851-857 [Abstract] [Full Text]  
  • Baishanbo, A., Gargala, G., Duclos, C., Francois, A., Rossignol, J.-F., Ballet, J. J., Favennec, L. (2006). Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model. J Antimicrob Chemother 57: 353-355 [Abstract] [Full Text]  
  • Gargala, G., Baishanbo, A., Favennec, L., Francois, A., Ballet, J. J., Rossignol, J.-F. (2005). Inhibitory Activities of Epidermal Growth Factor Receptor Tyrosine Kinase-Targeted Dihydroxyisoflavone and Trihydroxydeoxybenzoin Derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum Development. Antimicrob. Agents Chemother. 49: 4628-4634 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»